Core Viewpoint - Quest Diagnostics (DGX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements, particularly due to institutional investors' reliance on these estimates for valuation [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations for stocks, prompting institutional investors to buy or sell, thus affecting stock prices [4]. Company Performance and Outlook - The upgrade for Quest Diagnostics signifies an improvement in its underlying business, which is expected to drive the stock price higher as investors respond positively to this trend [5][10]. - Analysts project that Quest Diagnostics will earn $9.70 per share for the fiscal year ending December 2025, with a slight increase of 0.1% in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system categorizes stocks based on earnings estimate revisions, with only the top 20% of stocks receiving a "Strong Buy" or "Buy" rating, indicating superior potential for market-beating returns [9][10]. - The Zacks Rank 2 for Quest Diagnostics places it among the top 20% of stocks covered by Zacks, suggesting a favorable outlook for the stock in the near term [10].

Financial Results Announcement - Labcorp Holdings Inc. will release its financial results for the second quarter of 2025 before the market opens on July 24, 2025 [1] - A conference call and webcast will be held at 9 a.m. ET on the same day to discuss the results [1] Webcast Details - The call will be available via live webcast on the Labcorp Investor Relations website, with registration required for dial-in access [2] - Participants are encouraged to join 10 minutes early, but can register and join at any time during the call [2] Replay Information - A replay of the webcast will be accessible approximately two hours after the live event and will remain available until July 11, 2026 [3] Company Overview - Labcorp is a global leader in laboratory services, aiding healthcare professionals and researchers in decision-making [4] - The company employs nearly 70,000 individuals and operates in approximately 100 countries, supporting over 75% of new drugs approved by the FDA in 2024 [4] - Labcorp conducts more than 700 million tests annually for patients worldwide [4]

Core Viewpoint - Labcorp has launched a new blood-based biomarker test, the pTau-217/Beta Amyloid 42 Ratio, which aids in the diagnosis of Alzheimer's disease and meets performance criteria for confirming amyloid pathology consistent with the disease [1][2]. Group 1: Test Features and Benefits - The pTau-217/Beta Amyloid 42 Ratio test provides results comparable to positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) testing, supporting neurologists and dementia specialists in diagnosing Alzheimer's disease [2]. - This test has a sensitivity and specificity of 95%, which is substantially equivalent to the performance of amyloid PET imaging and CSF testing [8]. - Blood draws for the test can be conducted in a physician's office or at any of Labcorp's over 2,000 Patient Service Centers (PSCs) nationwide, making it more accessible [8]. Group 2: Market Context and Impact - An estimated 6.9 million Americans are currently living with Alzheimer's disease, a figure projected to nearly double by 2050, highlighting the growing need for effective diagnostic tools [3]. - The average time from the onset of symptoms to diagnosis is approximately 2.8 years, indicating a significant delay in the current diagnostic process [3]. - The introduction of this test aims to reduce the time and anxiety associated with diagnosing Alzheimer's disease, enabling more timely and informed treatment decisions for patients and their families [4]. Group 3: Company Overview - Labcorp is a global leader in laboratory services, providing insights and advancing science to improve health through diagnostics and drug development capabilities [7]. - The company employs nearly 70,000 individuals and serves clients in approximately 100 countries, supporting over 75% of new drugs approved by the FDA in 2024 [7].

Core Viewpoint - Labcorp is expanding its offerings to include FDA-approved self-collection solutions for HPV and STI testing, aiming to improve access to cervical cancer screenings and sexually transmitted infection tests [1][4][5] Group 1: Cervical Cancer Screening - Each year, over 13,000 women in the U.S. are diagnosed with cervical cancer, with approximately 4,000 deaths from this preventable disease [3] - HPV testing is essential for early intervention and treatment, yet one in four women of screening age were not up to date with cervical cancer screening recommendations in 2021 [3] - The FDA approved self-collection tests for cervical cancer screenings in 2024, providing a less invasive alternative to traditional Pap smears [4][5] Group 2: STI Testing - Labcorp will offer a vaginal swab self-collect option for STI testing, including chlamydia, gonorrhea, trichomonas, and mycoplasma genitalium [5] - In 2023, the CDC reported 2.4 million cases of STIs diagnosed and reported, highlighting the need for early detection to minimize long-term effects [5] - Self-collection for STI testing can empower individuals to take control of their sexual health and expedite the diagnosis-to-treatment timeline [6] Group 3: Accessibility and Convenience - The self-collection options will be available starting April 7, allowing patients to complete tests privately in healthcare settings or at Labcorp's 2,200 Patient Service Centers nationwide [7][9] - Results from the tests will be sent electronically to both the ordering physician and the patient via their Labcorp Patient account [9]